Literature DB >> 31648363

A time-dependent contribution of hippocampal CB1 , CB2 and PPARγ receptors to cannabidiol-induced disruption of fear memory consolidation.

Ana Maria Raymundi1, Thiago R da Silva1, Aleksander R Zampronio1, Francisco S Guimarães2, Leandro J Bertoglio3, Cristina A J Stern1.   

Abstract

BACKGROUND AND
PURPOSE: In preclinical studies, cannabidiol (CBD) mitigates fear memories by facilitating their extinction or interfering with their generalization and reconsolidation. The brain regions and mechanisms underlying these effects, and their temporal window, are still poorly understood. Here, we have investigated related questions in the dorsal hippocampus (DH) during contextual fear consolidation. EXPERIMENTAL APPROACH: Adult male Wistar rats received CBD (10-30 pmol) intra-DH immediately, 1 or 3 hr after fear conditioning. Effects of CBD on consolidation were inferred behaviourally and by analysing expression of the activity-regulated, cytoskeleton-associated (Arc) protein. The contribution of anandamide, CB1 , CB2 , 5-HT1A , A2A , and PPARγ receptors was also assessed. KEY
RESULTS: CBD impaired memory consolidation when given immediately or 1 hr after fear conditioning, but not after 3 hr. Expression of Arc protein in DH was reduced by systemic CBD treatment in both cases. Immediately after fear conditioning, CBD effects were abolished by CB1 or CB2 receptor blockade, partly reduced by 5-HT1A or A2A antagonism, and remained unchanged after antagonism of PPARγ receptors. One hour after fear conditioning, CBD effects were prevented only by PPARγ receptor antagonism. Also, inhibition of fatty acid amide hydrolase by URB597, impaired memory consolidation when infused immediately, but not 1 hr after fear conditioning. CONCLUSIONS AND IMPLICATIONS: CBD disrupts memory consolidation up to 1 hr after fear conditioning, allowing an extended window of opportunity to mitigate aversive memories after their acquisition. Our results suggest time-dependent participation of anandamide, CB1 , CB2 and PPARγ receptors in the DH, during this process.
© 2019 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31648363      PMCID: PMC7024734          DOI: 10.1111/bph.14895

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  63 in total

1.  Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS.

Authors:  S Moreno; S Farioli-Vecchioli; M P Cerù
Journal:  Neuroscience       Date:  2004       Impact factor: 3.590

Review 2.  Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

Authors:  Javier Fernández-Ruiz; Onintza Sagredo; M Ruth Pazos; Concepción García; Roger Pertwee; Raphael Mechoulam; José Martínez-Orgado
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

Review 3.  Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders.

Authors:  Jonathan L C Lee; Leandro J Bertoglio; Francisco S Guimarães; Carl W Stevenson
Journal:  Br J Pharmacol       Date:  2017-03-09       Impact factor: 8.739

4.  Effects of post-training hippocampal injections of midazolam on fear conditioning.

Authors:  Georgette M Gafford; Ryan G Parsons; Fred J Helmstetter
Journal:  Learn Mem       Date:  2005 Nov-Dec       Impact factor: 2.460

5.  Selective post-training time window for memory consolidation interference of cannabidiol into the prefrontal cortex: Reduced dopaminergic modulation and immediate gene expression in limbic circuits.

Authors:  Matheus Teixeira Rossignoli; Cleiton Lopes-Aguiar; Rafael Naime Ruggiero; Raquel Araujo Do Val da Silva; Lezio Soares Bueno-Junior; Ludmyla Kandratavicius; José Eduardo Peixoto-Santos; José Alexandre Crippa; Jaime Eduardo Cecilio Hallak; Antonio Waldo Zuardi; Raphael Escorsim Szawka; Janete Anselmo-Franci; João Pereira Leite; Rodrigo Neves Romcy-Pereira
Journal:  Neuroscience       Date:  2017-03-24       Impact factor: 3.590

Review 6.  THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Enzymes.

Authors:  Stephen P H Alexander; Doriano Fabbro; Eamonn Kelly; Alistair Mathie; John A Peters; Emma L Veale; Jane F Armstrong; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2019-12       Impact factor: 8.739

7.  A peripheral immune response to remembering trauma contributes to the maintenance of fear memory in mice.

Authors:  Matthew B Young; Leonard L Howell; Lauren Hopkins; Cassandra Moshfegh; Zhe Yu; Lauren Clubb; Jessica Seidenberg; Jeanie Park; Adam P Swiercz; Paul J Marvar
Journal:  Psychoneuroendocrinology       Date:  2018-05-21       Impact factor: 4.905

8.  Role of endocannabinoids in the hippocampus and amygdala in emotional memory and plasticity.

Authors:  Amir Segev; Nachshon Korem; Tomer Mizrachi Zer-Aviv; Hila Abush; Rachel Lange; Garrett Sauber; Cecilia J Hillard; Irit Akirav
Journal:  Neuropsychopharmacology       Date:  2018-06-27       Impact factor: 7.853

9.  On disruption of fear memory by reconsolidation blockade: evidence from cannabidiol treatment.

Authors:  Cristina A J Stern; Lucas Gazarini; Reinaldo N Takahashi; Francisco S Guimarães; Leandro J Bertoglio
Journal:  Neuropsychopharmacology       Date:  2012-05-02       Impact factor: 7.853

10.  THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Nuclear hormone receptors.

Authors:  Stephen P H Alexander; John A Cidlowski; Eamonn Kelly; Alistair Mathie; John A Peters; Emma L Veale; Jane F Armstrong; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2019-12       Impact factor: 8.739

View more
  7 in total

1.  A time-dependent contribution of hippocampal CB1 , CB2 and PPARγ receptors to cannabidiol-induced disruption of fear memory consolidation.

Authors:  Ana Maria Raymundi; Thiago R da Silva; Aleksander R Zampronio; Francisco S Guimarães; Leandro J Bertoglio; Cristina A J Stern
Journal:  Br J Pharmacol       Date:  2020-01-21       Impact factor: 8.739

Review 2.  Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.

Authors:  María S García-Gutiérrez; Francisco Navarrete; Ani Gasparyan; Amaya Austrich-Olivares; Francisco Sala; Jorge Manzanares
Journal:  Biomolecules       Date:  2020-11-19

Review 3.  Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System.

Authors:  Ana Lago-Fernandez; Sara Zarzo-Arias; Nadine Jagerovic; Paula Morales
Journal:  Int J Mol Sci       Date:  2021-01-20       Impact factor: 5.923

Review 4.  Neurogenic Interventions for Fear Memory via Modulation of the Hippocampal Function and Neural Circuits.

Authors:  Hee Ra Park; Mudan Cai; Eun Jin Yang
Journal:  Int J Mol Sci       Date:  2022-03-25       Impact factor: 5.923

5.  Cannabidiol Prevents Spontaneous Fear Recovery after Extinction and Ameliorates Stress-Induced Extinction Resistance.

Authors:  Eleni P Papagianni; William G Warren; Helen J Cassaday; Carl W Stevenson
Journal:  Int J Mol Sci       Date:  2022-08-19       Impact factor: 6.208

6.  Mechanisms Underlining Inflammatory Pain Sensitivity in Mice Selected for High and Low Stress-Induced Analgesia-The Role of Endocannabinoids and Microglia.

Authors:  Piotr Poznanski; Joanna Giebultowicz; Justyna Durdzinska; Tomasz Kocki; Mariusz Sacharczuk; Magdalena Bujalska-Zadrozny; Anna Lesniak
Journal:  Int J Mol Sci       Date:  2022-10-02       Impact factor: 6.208

7.  The Cannabis Constituent Cannabigerol Does Not Disrupt Fear Memory Processes or Stress-Induced Anxiety in Mice.

Authors:  Cilla Zhou; Neda Assareh; Jonathon C Arnold
Journal:  Cannabis Cannabinoid Res       Date:  2021-06-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.